Premium
Topical application of PPAR α (but not β/δ or γ) suppresses atopic dermatitis in NC /Nga mice
Author(s) -
Chiba T.,
Takeuchi S.,
Esaki H.,
Yamamura K.,
Kurihara Y.,
Moroi Y.,
Furue M.
Publication year - 2012
Publication title -
allergy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.363
H-Index - 173
eISSN - 1398-9995
pISSN - 0105-4538
DOI - 10.1111/j.1398-9995.2012.02844.x
Subject(s) - atopic dermatitis , activator (genetics) , receptor , peroxisome proliferator activated receptor , dermis , immunology , medicine , pharmacology , chemistry , pathology
Background Peroxisome proliferator‐activated receptors ( PPAR s) are nuclear receptors, which regulate not only adipogenesis and proliferation/differentiation but also the immune response of cells. Because topical application of the activators of some PPAR isoforms improved clinical symptoms in patients with atopic dermatitis ( AD ), we investigated the role of PPAR activators using a murine AD model in NC /Nga mice; to the best of our knowledge, this has not been previously reported. Methods Activators of three PPAR isoforms (α, β/δ, γ) were topically applied on inflamed skin in a murine AD model that was developed by repeated topical application of mite antigen in NC /Nga mice. The efficacy of each topical PPAR activator was evaluated immunologically and serologically. Results Topical application of the PPAR α activator, but not of the activators of PPAR β/δ or PPAR γ, improved clinical dermatitis, reduced inflammatory cell infiltration in the dermis, and alleviated the elevation of serum IgE levels. In addition, PPAR α expression was downregulated in the epidermis in our murine AD model, as is seen in patients with AD . Conclusions Topical application of PPAR α activator could be a potent therapeutic agent for patients with AD and could take the place of topical steroid treatments.